On July 15, 2025, Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., announced that the FDA has approved KIRSTY (insulin aspart-xjhz injection), 100 units/mL, as the first and...more
Goodwin is presenting a two-part publication series covering life sciences trends involving license deals, M&A, and financing for Greater China’s life sciences sector. ...more
11/11/2024
/ Acquisitions ,
AstraZeneca ,
Biotechnology ,
Bristol-Myers Squibb ,
China ,
Johnson & Johnson ,
Life Sciences ,
Medical Devices ,
Mergers ,
Novartis ,
Pharmaceutical Industry ,
Popular